Oncolytic Virus Therapy in Solid Tumors: Clinical Translation Challenges and Strategies

Siru Chen

doi:10.47297/wspbdsWSP2752-630512.20260601

PDF
Export
Share
Collection
Album

Oncolytic Virus Therapy in Solid Tumors: Clinical Translation Challenges and Strategies

Volume 6, Issue 1

Views: 0 Downloads: 0

Oncolytic Virus Therapy in Solid Tumors: Clinical Translation Challenges and Strategies
Oncolytic Virus Therapy in Solid Tumors: Clinical Translation Challenges and Strategies
China Pharmaceutical University, Nanjing, Jiangsu, 211198, China
Vol. 6, Issue 1, Pages: 53-57(2026)
Published：30 March 2026
DOI：10.47297/wspbdsWSP2752-630512.20260601
Accepted：

Scan QR Code

Chen Siru.Oncolytic Virus Therapy in Solid Tumors: Clinical Translation Challenges and Strategies[J].Biomedical Data Science,2026,06(01):53-57.
DOI：

Chen Siru.Oncolytic Virus Therapy in Solid Tumors: Clinical Translation Challenges and Strategies[J].Biomedical Data Science,2026,06(01):53-57. DOI： 10.47297/wspbdsWSP2752-630512.20260601.

摘要

Abstract

Oncolytic viruses (OVs)

as a type of tumor-targeted immunotherapy

show great potential in solid tumor treatment by selectively infecting and lysing tumor cells

while activating the host's anti-tumor immune response. Although products like H101 and T-VEC have been approved

their clinical translation still faces a core dilemma: feasibility of the mechanism does not equal clinical efficacy. Currently

the clinical translation of oncolytic viruses faces three major challenges. First

the preclinical-to-clinical translation dilemma

as existing animal models are unable to accurately predict the replication efficiency and immune response of the virus in the human body; second

the challenges at the clinical development stage

due to the lack of effective biomarkers to guide patient selection; and third

delivery and pharmacokinetics issues

where intratumoral injection is only suitable for superficial tumors

while systemic administration faces dual barriers from immune and physical obstacles in the tumor microenvironment. To address these challenges

the article proposes corresponding optimization strategies: first

optimizing viral vectors to enhance virus targeting and immune evasion capabilities; second

upgrading delivery systems to achieve systemic targeted delivery of the virus; and third

optimizing dosing regimens and combination therapies to induce immunogenic cell death and improve the tumor microenvironment. In the future

with advancements in precision medicine and delivery technologies

oncolytic virus therapy is expected to bring new breakthroughs in solid tumor treatment.

关键词

Keywords

references

KAUR B , CHIOCCA E A , CRIPE T P . Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress [J ] . Curr Pharm Biotechnol , 2012 , 13 ( 9 ): 1842 - 51 .

ALKAYYAL A A . Insights from veterinary models for advancing oncolytic virotherapy through comparative oncology [J ] . Front Mol Biosci , 2025 , 12 : 1615393 .

EL-TANANI M , RABBANI S A , PATNI M A , et al . Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis [J ] . Vaccines (Basel) , 2025 , 13 ( 10 ).

SEYMOUR L , BOGAERTS J , PERRONE A , et al . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J ] . Lancet Oncol , 2017 , 18 ( 3 ): e143 - e52 .

LAU P , LIANG L , CHEN X , et al . Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis [J ] . EClinicalMedicine , 2025 , 86 : 103362 .

PENG Z , KALIM M , LU Y . Improving systemic delivery of oncolytic virus by cellular carriers [J ] . Cancer Biol Med , 2025 , 21 ( 12 ): 1104 - 19 .

SOKO G F , KOSGEI B K , MEENA S S , et al . Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses [J ] . Front Immunol , 2024 , 15 : 1535647 .

RANKI T , HEMMINKI A . Serotype chimeric human adenoviruses for cancer gene therapy [J ] . Viruses , 2010 , 2 ( 10 ): 2196 - 212 .

ZHU J , MA J , HUANG M , et al . Emerging delivery strategy for oncolytic virotherapy [J ] . Mol Ther Oncol , 2024 , 32 ( 2 ): 200809 .

WARRICKER F , KHAKOO S I , BLUNT M D . The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma [J ] . J Transl Genet Genom , 2021 , 5 : 304 - 22 .

SU C Q , WANG X H , CHEN J , et al . Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma [J ] . World J Gastroenterol , 2006 , 12 ( 47 ): 7613 - 20 .

DAVIS J J , WANG L , DONG F , et al . Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter [J ] . Cancer Gene Ther , 2006 , 13 ( 7 ): 720 - 3 .

CHEN X , WU S , ZHANG Y , et al . Hydrogels for Cancer Immunotherapy: Strategies From Construction to Application [J ] . MedComm (2020), 2026 , 7 ( 2 ): e70615 .

SHIN D H , NGUYEN T , OZPOLAT B , et al . Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy [J ] . J Immunother Cancer , 2021 , 9 ( 4 ).

SINGER Z S , PABóN J , HUANG H , et al . Engineered bacteria launch and control an oncolytic virus [J ] . Nat Biomed Eng , 2025 .

RUSSELL L , PENG K W , RUSSELL S J , et al . Oncolytic Viruses: Priming Time for Cancer Immunotherapy [J ] . BioDrugs , 2019 , 33 ( 5 ): 485 - 501 .

Alert me when the article has been cited

Submit

Research Progress of Nanomedicine in the Treatment of Lung Cancer

Chlorogenic Acid's Antioxidant Defense: A Key Pharmacological Mechanism Against Metabolic Diseases

Challenges and prospects of CAR-T cell therapy in colorectal cancer (CRC)

Related Author

Erlan Yi Oaks Christian School, La Tienda Road31749, Westlake Village

Zehan Li College of Food Science and Engineering, Jilin Agricultural University

Yanan Lv The Affiliated Middle School of Huazhong University of Science and Technology

Related Institution

Oaks Christian School, La Tienda Road31749, Westlake Village

College of Food Science and Engineering, Jilin Agricultural University

The Affiliated Middle School of Huazhong University of Science and Technology

⁰